parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Article Details

Citation

Galbraith KM, Ng AC, Eggers BJ, Kuchel CR, Eggers CH, Samuels DS

parC mutations in fluoroquinolone-resistant Borrelia burgdorferi.

Antimicrob Agents Chemother. 2005 Oct;49(10):4354-7.

PubMed ID
16189120 [ View in PubMed
]
Abstract

We have isolated in vitro fluoroquinolone-resistant mutants of the Lyme disease agent, Borrelia burgdorferi. Mutations in parC, which encodes a subunit of topoisomerase IV, were associated with loss of susceptibility to sparfloxacin, moxifloxacin, and Bay-Y3118, but not ciprofloxacin. This is the first description of fluoroquinolone resistance in the spirochete phylum.

DrugBank Data that Cites this Article

Drug Targets
DrugTargetKindOrganismPharmacological ActionActions
SparfloxacinDNA topoisomerase 4 subunit AProteinHaemophilus influenzae (strain ATCC 51907 / DSM 11121 / KW20 / Rd)
Yes
Inhibitor
Details